Spots Global Cancer Trial Database for dtic
Every month we try and update this database with for dtic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| HD10 for Early Stages | NCT00265018 | Hodgkin´s Lymph... | Adriamycin Bleomycin Vinblastine DTIC 30 Gy IF-RT 20 Gy IF-RT | 16 Years - 75 Years | University of Cologne | |
| Rituximab and ABVD for Hodgkin's Patients | NCT00504504 | Lymphoma | Rituximab Adriamycin Bleomycin Vinblastine Dacarbazine (DT... | 16 Years - | M.D. Anderson Cancer Center | |
| Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC) | NCT01009177 | Melanoma | Bosentan Placebo | 18 Years - 70 Years | Actelion | |
| Rituximab and ABVD for Hodgkin's Patients | NCT00504504 | Lymphoma | Rituximab Adriamycin Bleomycin Vinblastine Dacarbazine (DT... | 16 Years - | M.D. Anderson Cancer Center | |
| A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma | NCT02076646 | Metastatic Mela... | L19IL2 - Ph I L19IL2 at RD - ... DTIC | 18 Years - 70 Years | Philogen S.p.A. | |
| A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma | NCT00395070 | Metastatic Mela... | Allovectin-7® Dacarbazine (DT... Temozolomide (T... | 18 Years - | Vical | |
| Rituximab and ABVD for Hodgkin's Patients | NCT00504504 | Lymphoma | Rituximab Adriamycin Bleomycin Vinblastine Dacarbazine (DT... | 16 Years - | M.D. Anderson Cancer Center | |
| A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma | NCT02076646 | Metastatic Mela... | L19IL2 - Ph I L19IL2 at RD - ... DTIC | 18 Years - 70 Years | Philogen S.p.A. | |
| Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma | NCT00412581 | Melanoma | Lenalidomide Dacarbazine | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine | NCT00542893 | Advanced Melano... | Genasense® (G31... Genasense follo... DTIC alone; the... | 18 Years - | Genta Incorporated | |
| Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma | NCT00715793 | Malignant Melan... | Decitabine Temozolomide biopsy | 18 Years - | University of Pittsburgh | |
| Rituximab and ABVD for Hodgkin's Patients | NCT00504504 | Lymphoma | Rituximab Adriamycin Bleomycin Vinblastine Dacarbazine (DT... | 16 Years - | M.D. Anderson Cancer Center | |
| HD11 for Intermediate Stages | NCT00264953 | Hodgkin´s Lymph... | Adriamycin Bleomycin Vinblastine DTIC Etoposide Procarbazine Prednisone Vincristine radiation thera... | 16 Years - 75 Years | University of Cologne | |
| Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma | NCT00327600 | Malignant Melan... | imexon DTIC | - | AmpliMed Corporation | |
| A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine | NCT00542893 | Advanced Melano... | Genasense® (G31... Genasense follo... DTIC alone; the... | 18 Years - | Genta Incorporated | |
| Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma | NCT00412581 | Melanoma | Lenalidomide Dacarbazine | 18 Years - | M.D. Anderson Cancer Center | |
| Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients | NCT01056679 | Hodgkin Lymphom... | Doxorubicine DTIC Lenalidomide Vinblastine | 60 Years - 75 Years | University of Cologne | |
| Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients | NCT00553618 | Metastatic Mela... | Proleukin and D... | 18 Years - | University of Louisville | |
| Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | NCT03755804 | Hodgkin Lymphom... | bendamustine Etoposide Doxorubicin Bleomycin Vincristine Vinblastine Prednisone Filgrastim Brentuximab Ved... Cyclophosphamid... DTIC Quality of Life... Radiotherapy | - 25 Years | St. Jude Children's Research Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
